OBJECTIVE: Mycoplasma genitalium (MG) is a microorganism related to sexually transmitted infections. Antibiotic resistance of MG leads to an increase in treatment failure rates and the persistence of the infection. The aim of this study was to describe the most frequent mutations associated with azithromycin and moxifloxacin resistance in our geographical area. METHODS: A prospective study from May 2019 to May 2023 was performed. MG-positive samples were collected. Real-time PCRs (AllplexTM MG-AziR Assay and AllplexTM MG-MoxiR Assay, Seegene) were performed in MG positive samples to detect mutations in 23S rRNA V domain and parC gene. RESULTS: A 37.1% of samples presented resistance determinants to azithromycin and the most common mutation detected was A2059G (57.9%). Resistance to moxifloxacin was studied in 72 azithromycin-resistant samples and 36.1% showed mutations, being G248T the most prevalent (73.1%). CONCLUSIONS: The resistance to different lines of treat ment suggests the need for a targeted therapy and the performing of a test of cure afterwards.
Anti-Bacterial Agents , Azithromycin , Drug Resistance, Bacterial , Moxifloxacin , Mutation , Mycoplasma Infections , Mycoplasma genitalium , Mycoplasma genitalium/drug effects , Mycoplasma genitalium/genetics , Moxifloxacin/pharmacology , Moxifloxacin/therapeutic use , Azithromycin/pharmacology , Azithromycin/therapeutic use , Spain , Humans , Prospective Studies , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Bacterial/genetics , Mycoplasma Infections/drug therapy , Mycoplasma Infections/microbiology , Female , Male , Microbial Sensitivity Tests , RNA, Ribosomal, 23S/genetics , Adult , DNA Topoisomerase IV/genetics
